MARKET

LFCR

LFCR

Lifecore Biomedical Inc
NASDAQ
6.35
-0.09
-1.40%
Closed 16:00 05/02 EDT
OPEN
6.50
PREV CLOSE
6.44
HIGH
6.50
LOW
6.23
VOLUME
133.34K
TURNOVER
0
52 WEEK HIGH
11.46
52 WEEK LOW
4.060
MARKET CAP
193.97M
P/E (TTM)
-1.9107
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at LFCR last week (0422-0426)?
Weekly Report · 4d ago
Cove Street Capital Q1 2024 Letter To Shareholders
First quarter of calendar year 2024 was mostly more of the recent same for Cove Street Capital. The star of the quarter was clearly Liberty TripAdvisor Holdings. E.W. Scripps continues to be a "very, very cheap" stock. The U.S. Economy managed another positive quarter.
Seeking Alpha · 04/23 10:00
Weekly Report: what happened at LFCR last week (0415-0419)?
Weekly Report · 04/22 09:18
Laughing Water Capital - Lifecore Biomedical: Getting Closer To Massive Improvements In Earnings Power
Lifecore Biomedical is getting closer to massive improvements in earnings power. A strategic review of the company ended without a sale in late March. The company is bringing on additional capacity that was planned for 4 years ago. New CEO Paul Josephs has been named and will be starting in May.
Seeking Alpha · 04/21 09:00
White Falcon Capital - Lifecore Biomedical: Potential For Rapid Growth In Earnings And FCF Surge
Lifecore Biomedical is increasing capacity and most of this capacity is already paid for, potentially leading to a surge in free cash flow. The company's revenues can increase 2-3x over the next 4 years. White Falcon Capital bought more shares at $4.8 to bring Lifecore back to a 3% position.
Seeking Alpha · 04/20 15:10
Lifecore Biomedical Faces Nasdaq Delisting Challenges
TipRanks · 04/19 20:53
Lifecore Biomedical gets Nasdaq notice regarding delayed quarterly report
Lifecore Biomedical gets Nasdaq notice regarding delayed quarterly report. Nasdaq will consider the delinquency in the filing of the Q3 Form 10-Q. The notice has no immediate effect on the company's continued listing on the Nasdaq Global Select Market.
Seeking Alpha · 04/19 20:42
Lifecore Biomedical, Inc. Receives Notice From Nasdaq Regarding Delayed Quarterly Report For The Fiscal Quarter Ended February 25, 2024 And Its Continued Delay In Filing Its Quarterly Report On Form 10-Q For The Quarterly Periods Ended August 27, 2023 And November 29, 2023
Lifecore Biomedical, Inc. Received a notification letter from Nasdaq on April 15, 2024. The Company continues not to be in compliance with the requirements for continued listing on the Nasdaq Global Select Market. The Notice has no immediate effect on the listing or trading of the Company's common stock.
Benzinga · 04/19 20:41
More
About LFCR
Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO). The Company designs, develops, manufactures and sells differentiated products for biomaterials markets and license technology applications to partners. The Company offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. It is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a spectrum of medical conditions and procedures. The Company uses its fermentation process and aseptic formulation and filling expertise to develop HA-based products for multiple applications and to take advantage of non-HA devices and drug opportunities.

Webull offers Lifecore Biomedical Inc stock information, including NASDAQ: LFCR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LFCR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LFCR stock methods without spending real money on the virtual paper trading platform.